Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/CN2018/075867, filed Feb 8, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,066,457 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 11,472,858 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · Low confidence | Abelzeta Inc. | In force | Low confidence | ||
| US 11,608,369 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 11,618,778 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 12,583,903 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · Low confidence | Abelzeta Inc. | In force | Low confidence | ||
| US 12,747,279 | Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| Application 18/263,050 | Chimeric Antigen Receptors Targeting CD20 Pending Not granted | Abelzeta Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Abelzeta Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.